Dantrolene analogues revisited: General synthesis and specific functions capable of discriminating two kinds of Ca2+ release from sarcoplasmic reticulum of mouse skeletal muscle

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 5, 2003, Pages 663-673

  Hosoya, Takamitsu ^a,b   Aoyama, Hiroshi ^b   Ikemoto, Takaaki ^c   Kihara, Yasutaka ^c   Hiramatsu, Toshiyuki ^b   Endo, Makoto ^c   Suzuki, Masaaki ^a,b  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(5 PHENYLFURFURYLIDENE)AMINO]IMIDAZOLIDINE 2 4 DIONE; 1 [[5 (1 NAPHTHYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (2 METHOXYPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (2 NITROPHENYL) 2 THENYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (2 NITROPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDENE 2,4 DIONE; 1 [[5 (2,3,4,5,6 PENTAFLUOROPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (2,6 DINITROPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (3 METHOXYPHENYL)FUFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (3 NITROPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (4 CYANOPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (4 FLUOROPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (4 HYDROXYPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (4 METHOXYPHENYL)FUFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (4 METHYLPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2 4 DIONE; 1 [[5 (4 NITROPHENYL) 2 THENYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (4 PHENYLPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (4 TRIFLUOROMETHANESUFONYLPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; 1 [[5 (4 TRIFLUOROMETHYLPHENYL)FURFURYLIDENE]AMINO]IMIDAZOLIDINE 2,4 DIONE; CALCIUM ION; DANTROLENE; GIF 0166; GIF 0185; GIF 0248; IMIDAZOLIDINE DERIVATIVE; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; ISOMER; MOUSE; MUSCLE CELL; MUSCLE TWITCH; NONHUMAN; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE;

ANIMALS; CALCIUM; DANTROLENE; INDICATORS AND REAGENTS; MICE; MUSCLE CONTRACTION; MUSCLE RELAXANTS, CENTRAL; MUSCLE, SKELETAL; SARCOPLASMIC RETICULUM; STRUCTURE-ACTIVITY RELATIONSHIP;

LATEOLABRAX JAPONICUS;

EID: 0037355263     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00600-4     Document Type: Article

References (50)

1. Simmons R.M. Muscular Contraction. 1992;Cambridge University Press, New York.
2. Endo M. Curr. Top. Membr. Transp. 25:1985;181.
3. (a) Schneider M.F. Annu. Rev. Physiol. 56:1994;463.
4. (b) Ríos E., Pizarro G. Physiol. Rev. 71:1991;849.
5. (c) Sitsapesan R., Williams A.J. The Structure and Function of Ryanodine Receptors. 1998;Imperial College, London.
6. Endo, M.; Ikemoto, T. In Pharmacology of Ionic Channel Function. Activators and Inhibitors; Endo, M., Kurachi, Y., Mishina, M., Eds.; Springer: Berlin, 2000; p 583.
7. Iino M. Japan. J. Physiol. 49:1999;325.
8. Kasai M., Kawasaki T., Yamaguchi N. Biophys. Chem. 82:1999;173, and references cited therein.
9. (a) Näbauer M., Callewaert G., Cleemann L., Morad M. Science. 244:1989;800.
10. (b) Bers D.M., Perez-Reyes E. Cardiovasc. Res. 42:1999;339.
11. Ward A., Chaffman M.O., Sorkin E.M. Drugs. 32:1986;130.
12. (a) Snyder H.R. Jr., Davis C.S., Bickerton R.K., Halliday R.P. J. Med. Chem. 10:1967;807.
13. (b) Davis, C. S.; Snyder, H. R., Jr. US Patent 3,415,821, 1968.
14. (a) Ellis K.O., Bryant S.H. Naunyn-Schmiedeberg's Arch. Pharmacol. 274:1972;107.
15. (b) Ellis K.O., Carpenter J.F. Naunyn-Schmiedeberg's Arch. Pharmacol. 275:1972;83.
16. (a) Endo M., Yagi S., Ishizuka T., Horiuti K., Koga Y., Amaha K. Biomed. Res. 4:1983;83.
17. (b) Harrison G.G. Br. J. Anesth. 47:1975;62.
18. (c) Kolb M.E., Horne M.L., Martz R. Anesthesiology. 56:1982;254.
19. (d) MacLennan D.H., Phillips M.S. Science. 256:1992;789.
20. (e) Louis C.F., Balog E.M., Fruen B.R. Biosci. Rep. 21:2001;155.
21. (a) Ohta T., Endo M. Proc. Jpn. Acad. 62:1986;329.
22. (b) Ohta T., Endo M., Nakano T., Morohoshi Y., Wanikawa K., Ohga A. Am. J. Physiol. 256:1989;C358.
23. Ikemoto T., Hosoya T., Aoyama H., Kihara Y., Suzuki M., Endo M. Br. J. Pharmacol. 134:2001;729.
24. Hosoya T., Aoyama H., Ikemoto T., Hiramatsu T., Kihara Y., Endo M., Suzuki M. Bioorg. Med. Chem. Lett. 12:2002;3263.
25. Ikemoto T., Endo M. Br. J. Pharmacol. 134:2001;719.
26. (a) Akashi, H.; Oda, R. J. Chem. Soc. Japan 1950, 53, 81; Chem. Abstr. 1953, 47, 2164e.
27. (a) Akashi, H.; Oda, R. J. Chem. Soc. Japan 1950, 53, 81; Chem. Abstr. 1953, 47, 2164e.
28. (b) Rondestvedt C.S. Jr. Org. React. 11:1960;189.
29. (c) Rondestvedt C.S. Jr. Org. React. 24:1976;225.
30. The low reproducibility for preparation of 5-phenyl-2-furaldehyde was reported: Davis C.S., Lougheed G.S. J. Heterocycl. Chem. 4:1967;153. We also failed to prepare methoxy- or methyl-substituted dantrolene congeners by this method.
31. Palnitkar S.S., Bin B., Jimenez L.S., Morimoto H., Williams P.G., Paul-Pletzer K., Parness J. J. Med. Chem. 42:1999;1872.
32. (a) Other methods for the synthesis of 5-aryl-2-furaldehyde: Stille reaction using 7a protected with ethylene acetal: Balachari, D.; Quinn. L.; O'Doherty, G.A. Tetrahedron Lett. 1999, 40, 4769.
33. (b) Suzuki reaction using 7b protected with ethylene acetal: McClure, M.S.; Roschangar, F.; Hodson, S.J.; Millar, A.; Osterhout, M.H. Synthesis 2001, 1681.
34. (c) Heck reaction: McClure, M.S.; Glover, B.; McSorley, E.; Millar, A.; Osterhout, M.H.; Roschangar, F. Org. Lett. 2001, 3, 1677.
35. (d) Coupling of aryl halides and triorganozincates: Gauthier, D.R. Jr.; Szumigala, R.H. Jr.; Dormer, P.G.; Armstrong, J.D. III; Volante, R.P.; Reider, P.J. Org. Lett. 2002, 4, 375.
36. (a) Stille J.K. Angew. Chem., Int. Ed. Engl. 25:1986;508.
37. (b) Farina V., Krishnamurthy V., Scott W.J. Org. React. 50:1997;1.
38. (c) Echavarren A.M., Stille J.K. J. Am. Chem. Soc. 109:1987;5478.
39. Denat F., Gaspard-Iloughmane H., Dubac J. Synthesis. 1992;954.
40. 3SnCl, -20°C to room temperature, 17 h, 91%. See also: Han, Y.; Roy, A.; Giroux, A. Tetrahedron Lett. 2000, 41, 5447.
41. Suzuki A. J. Organomet. Chem. 576:1999;147.
42. (b) Miyaura N., Suzuki A. Chem. Rev. 95:1995;2457.
43. Florentin D., Roques B.P., Fournie-Zaluski M.C. Bull. Soc. Chim. Fr. 1976;1999.
44. For inversed cross-coupling by the Suzuki reaction, namely, the combination of aryl boronic acids and 5-bromo-2-furaldehyde, see: Bussolari J.C., Rehborn D.C. Org. Lett. 1:1999;965. Our method is favorable in terms of the ready availability of aryl substrates.
45. (a) Traube W., Hoffa E. Chem. Ber. 31:1898;162.
46. (b) Gut J., Novácek A., Fiedler P. Collect. Czech. Chem. Commun. 33:1968;2087.
47. Grynkiewicz G., Poenie M., Tsien R.Y. J. Biol. Chem. 260:1985;3440.
48. (a) Parness J., Palnitkar S.S. J. Biol. Chem. 270:1995;18465.
49. (b) Salata J.J., Jalife J. J. Pharmacol. Exp. Ther. 220:1982;157.
50. For the inhibitory effect of 4-iodo congener of dantrolene (GIF-0146) on twitch contraction (35.6%), see ref 13.